ISSN: 2157-2526

Zeitschrift für Bioterrorismus und Bioverteidigung

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • CAS-Quellenindex (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Akademische Schlüssel
  • JournalTOCs
  • Forschungsbibel
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Ulrichs Zeitschriftenverzeichnis
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • SWB Online-Katalog
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

Development of new purified vero cell rabies vaccine (Rabivax-S) at the Serum Institute of India Pvt.Ltd

Ashish Sahai

Introduction: TRabies is a 100% vaccine-preventable disease. Rabies disease still causes human deaths in the endemic areas in Asia and Africa. A cheap, rabies vaccine for humans that could be used in mass vaccination campaigns would be a valuable weapon against rabies. Serum institute of India Pvt. Ltd. has developed a new purified vero cell inactivated and lyophilized rabies vaccine (Rabivax-S) which is now a WHO prequalified rabies vaccine. Methodology, Theoretical Orientation & Findings: Large scale production of Vero ATCC CCL81 cells were seeded in cell cube system. Then cells are infected with Pitman Moore (PM 3218) strain of rabies virus. After 48- 72 hrs, infected cells are washed. The multiple harvests are collected from one cell cube system and clarified by filtration. Clarified harvest is concentrated using tangential flow filtration system. Inactivation of rabies virus is done using beta-propiolactone (BPL). Next step of purification is done by affinity column chromatography in order to remove BSA and host cell DNA and diafiltration to remove high salt concentration. Purified rabies antigen is prepared by adding stabilizer to diafiltered antigen and finally filtered by 0.22 micron filtration and stored in ethyl vinyl acetate bags. A number of purified rabies antigen bags are blended to achieve set antigen content in final bulk. The liquid vaccine is filled in 1 ml USP type 1 clear and tubular vial and lyophilized. With the lyophilized vial of rabies vaccine 1.0 ml of sterile water for injection is supplied as a diluents. Conclusion & Significance: Study gives well developed new purified vero cell rabies vaccine (Rabivax-S), following all the GMP requirements. Animal study has demonstrated no toxicity issue. We evaluated its safety, toxicity and immunogenicity in post-exposure prophylaxis in clinical trials by IM and ID routes. This vaccine is good option among the available modern WHO prequalified rabies vaccine. Filling, lyophilization and packaging of final product